Once a bystander in the field of genetic medicine, AstraZeneca has started to make its ambitions clear over the last couple years.
The company stuck to the sidelines, while drugmakers such as Novartis, Bristol Myers Squibb and Gilead made significant investments in the field of cancer cell therapy in the last decade. But it has reportedly been quietly building internal development and manufacturing capabilities, and, in the last two years, signed alliances with startups working on newer approaches.
